Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Chidamide in Advanced Cervical Cancer
NCT04651127Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2020
- Primary completion
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab, tucidinostat in Cervical Cancer (CC), sponsored by Sun Yat-sen University. Started Nov 2020; status: terminated.
02
Drugs
toripalimabtucidinostat
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04651127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04651127.